1. Introduction {#sec1-marinedrugs-16-00335}
===============

Xanthones are a family of 9*H*-xanthen-9-one derivatives, which are widely distributed in plants, fungi, and lichens. The structures typically occur as either fully aromatized or aliphatic cyclic ketones with dihydro-, tetrahydro- or hexahydro- modifications, and poly-substitutions \[[@B1-marinedrugs-16-00335]\]. Among those structures, tetrahydroxanthone dimers, which were usually dimerized through biaryl C-C single bond with diverse dimeric patterns, such as 2--2′, 2--4′, 4--2′, and 4--4′ linkages \[[@B2-marinedrugs-16-00335]\], were frequently reported for their intriguing structures and impressive activities (antimicrobial, antiplasmodial, and antitumor bioactivities) \[[@B2-marinedrugs-16-00335],[@B3-marinedrugs-16-00335],[@B4-marinedrugs-16-00335]\]. However, tetrahydroxanthone dimers linked by diaryl ether bond were relatively rare, with only one instance reported \[[@B5-marinedrugs-16-00335]\].

In our previous study, the mangrove-associated fungus *Aspergillus versicolor* HDN1009 has been proven to be a fruitful producer of various xanthone analogues \[[@B2-marinedrugs-16-00335],[@B6-marinedrugs-16-00335]\]. In a recent work, UPLC-MS and cytotoxicity directed fractionation method were employed in a new trial of chemical study on HDN1009, to track unique xanthone structures. By carefully examining the UV absorption, predicted molecular weight, and the bioactivities of the unique peaks, three new tetrahydroxanthone dimers, named 5-*epi*-asperdichrome (**1**), versixanthones N (**2**), and O (**3**), were discovered and isolated, amongst which, 5-*epi*-asperdichrome (**1**) was the second example of tetrahydroxanthone dimers linked by a diaryl ether bond, which showed mild activities against four kinds of bacterial strains. Versixanthones N (**2**) and O (**3**) showed extensive cytotoxicities against five cancer cell lines. Herein, we will report the details of isolation, structure elucidation, and bioactivity evaluation of the above compounds.

2. Results and Discussion {#sec2-marinedrugs-16-00335}
=========================

The *Aspergillus versicolor* HDN1009 was cultured (50 L) under static conditions at 28 °C for 4 weeks, as previous reported in Reference \[[@B2-marinedrugs-16-00335]\]. Guided by UPLC-MS data, the EtOAc extract (30 g) of the fermentation was fractionated by silica gel vacuum liquid chromatography, C-18 ODS column chromatography, Sephadex LH-20 column chromatography, ODS MPLC, and finally HPLC to yield compounds **1** (4.0 mg), **2** (3.0 mg), and **3** (4.0 mg) ([Figure 1](#marinedrugs-16-00335-f001){ref-type="fig"}).

Compound **1** was isolated as a pale, yellow powder, with a molecular formula of C~32~H~30~O~14~, as deduced from HREIMS peak at *m*/*z* 639.1721 \[M + H\]^+^. The ^1^H and ^13^C NMR spectra of **1** indicated four methyls (including two methoxyls); two methylenes; nine sp^3^ methines (including two oxygenated methines and five aromatic methines); and 17 nonprotonated carbons (including two ester carbonyls, two conjugated ketone carbonyls), which were similar to the tetrahydroxanthone dimers we reported before in Reference \[[@B2-marinedrugs-16-00335]\]. Careful inspection of 1D NMR spectra revealed the twin resonances indicating a dimeric structure for **1**, which was quite similar to that of asperdichrome, with obvious differences only in chemical shifts and coupling constants of H-5, H-6, and H-7 (*δ*~H-5~: 3.95 d (11.3) in **1** vs. 4.12 d (1.4) in asperdichrome; *δ*~H-6~: 2.42 m in **1** vs. 2.14 m in asperdichrome; and *δ*~H-7~: 2.72 dd (6.4, 10.6); 2.29 dd (11.0, 15.4) in **1** vs. 2.40, dd (18.8, 6.3); 2.52, dd (18.8, 11.6) in asperdichrome) ([Figure 1](#marinedrugs-16-00335-f001){ref-type="fig"}, [Table 1](#marinedrugs-16-00335-t001){ref-type="table"} and [Supplementary Materials](#app1-marinedrugs-16-00335){ref-type="app"} [Figures S1--S21](#app1-marinedrugs-16-00335){ref-type="app"}) \[[@B5-marinedrugs-16-00335]\]. Further interpretation of 2D NMR spectra confirmed compound **1** shared an identical planar structure with asperdichrome; however, it possessed different stereochemistry ([Figure 2](#marinedrugs-16-00335-f002){ref-type="fig"}, [Table 1](#marinedrugs-16-00335-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00335-t002){ref-type="table"}).

The relative configuration of **1** was established as 5′*R\**, 6′*S\**, 10a′*R\**, 5*R\**, 6*S\**, 10a*R\** by the NOE correlations of Me-13 with H-6; H-5 with Me-11; Me-13′ with H-6′; and H-5′ with Me-11′, together with the coupling constant (^3^*J*~H-5~, ~H-6~ = ^3^*J* ~H-5′~, ~H-6′~ = 11.3 Hz). This suggested that 13-COOCH~3~ and OH-5 were located at the same side of ring A, whilst Me-11 was located at the other side; similarly, 13′-COOCH~3~ and OH-5′ were located at the same side of ring F, whilst Me-11′ was located at the other side ([Figure 3](#marinedrugs-16-00335-f003){ref-type="fig"}). The absolute configuration of **1** was determined by CD comparison. As there was no axial chirality between two monomeric units, the ECD curves were dominated by the chirality center elements \[[@B2-marinedrugs-16-00335],[@B5-marinedrugs-16-00335],[@B7-marinedrugs-16-00335]\]. Similar to versixanthones J, which we previously discovered from this strain, the positive n→π\* CD band at around 330 nm, indicated the *R*-configuration at C-10a/C-10a′ ([Figure 4](#marinedrugs-16-00335-f004){ref-type="fig"}) \[[@B2-marinedrugs-16-00335],[@B5-marinedrugs-16-00335],[@B7-marinedrugs-16-00335]\]. Combined with the relative configuration, the absolute configuration of compound **1** was assigned as 5′*R*, 6′*S*, 10a′*R*, 5*R*, 6*S*, 10a*R* and proved to be the 5-*epi* isomer of asperdichrome, and we named it 5-*epi*-asperdichrome.

Compounds **2** and **3** were also isolated as pale, yellow powder, and had the same molecular formula of C~32~H~30~O~14~, determined by HRESIMS detected at *m*/*z* 639.1721 \[M + H\]^+^. The almost twin resonances in the 1D NMR spectra, suggested that they were heterodimers of tetrahydroxanthones. A careful comparison of the NMR data of compounds **2** and **3** with versixanthone G, which we reported previously \[[@B2-marinedrugs-16-00335]\], suggested they had the same monomeric units. Further analysis of the 2D NMR data, revealed that the only difference between compounds **2**, **3** and versixanthone G were the linkage patterns of the two monomeric units. Compound **2** was constructed by connecting the two monomeric units via the linkage of C-2 and C-4′, based on the HMBC correlations from H-2′ to C-1′ and C-9a′; OH-1′ to C-1′; C-2′ and C-9a′; H~3~-11′ to C-2′; C-3′ and C-4′; OH-1 to C-1; C-2 and C-9a; and H-3 to C-4′. Based on the HMBC correlations from H-4′ to C-4a′ and C-3′; OH-1′ to C-1′; C-2′ and C-9a′; H~3~-11′ to C-2′; C-3′ and C-4′; OH-1 to C-1; C-2 and C-9a; and H-3 to C-2′ ([Figure 2](#marinedrugs-16-00335-f002){ref-type="fig"}), the planar structure of compound **3** was completed by connecting the two monomeric units via the linkage between C-4 and C-2′, which was the same as purpureone, whose absolute configuration has not been reported \[[@B8-marinedrugs-16-00335],[@B9-marinedrugs-16-00335]\].

The relative configurations of monomeric units in compounds **2** and **3**, were established to be the same as that of versixanthone G (5*R\**, 6*S\**, 10a*R\**, 5′*R\**, 10a′*R\**) by the coupling constant (^3^*J*~H-5~, ~H-6~ = 11.1 Hz), and the NOE correlations between Me-13 and H-6, H-5 and Me-11, Me-13′ and H-6′a (*δ*~H~ 2.12 for **2** and *δ*~H~ 2.23 for **3**), H-5′ and H-6′b (*δ*~H~ 2.00 for **2** and *δ*~H~ 2.10 for **3**) ([Figure 3](#marinedrugs-16-00335-f003){ref-type="fig"}, [Table 1](#marinedrugs-16-00335-t001){ref-type="table"}). Similar linkage type and substitution patterns with versixanthone G, suggest compounds **2** and **3** should also possess axial chirality \[[@B2-marinedrugs-16-00335]\]. The axial chiralities were further deduced by ECD exciton chirality method. Based on ECD spectra, the negative exciton couplings near 230 nm and 330 nm for **2** and **3**, which were similar with versixanthone G, allowing the assignment of both axial chiralities as a*R* \[[@B2-marinedrugs-16-00335]\]. Combined with the NOE correlations between two monomeric units (Me-13′ with H-3 and H-11 in **2**; Me-13′ with H-11 in **3**), the configurations at C-10a′ in both compounds were determined as *R*, and the absolute configurations of **2** and **3** were a*R*, 5*R*, 6*S*, 10a*R*, 5′*R*, 10a′*R,* accordingly.

Biological evaluation of all the compounds by an MTT method showed that **2** and **3** exhibited extensive cytotoxicity against five kinds of cancer cell lines (HL-60, K562, H1975, MGC803, and HO-8910) ([Table 3](#marinedrugs-16-00335-t003){ref-type="table"}), with IC~50~ values ranging from 1.7 μM to 16.1 μM. The results suggested that the connection type between the two monomers was very important. As with connection by oxygen atoms, the cytotoxic activity disappears completely. The antimicrobial activities of compound **1** were also evaluated and showed mild activities against *Vibrio parahemolyticus*, *Bacillus subtilis*, *Mycobacterium Phlei*, and *Pseudomonas aeruginosa*, with MIC values ranging from 100 μM to 200 μM ([Table 4](#marinedrugs-16-00335-t004){ref-type="table"}).

3. Materials and Methods {#sec3-marinedrugs-16-00335}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-16-00335}
------------------------------------

UV spectra were measured on a Beckman DU 640 spectrophotometer (Beckman Coulter Inc., Brea, CA, USA). Specific rotations were obtained by a JASCO P-1020 digital polarimeter (JASCO Corporation, Tokyo, Japan). ESIMS were obtained on a Thermo Scientific LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) or Micromass Q-TOF ULTIMA GLOBAL GAA076 LC Mass spectrometer (Wasters Corporation, Milford, MA, USA). NMR spectra were recorded on an Agilent 500 MHz DD2 spectrometer (Agilent Technologies Inc., Santa Clara, CA, USA), using TMS as an internal standard and chemical shifts were recorded as *δ*-values. Semi-preparative HPLC employed an ODS column (HPLC (YMC-Pack ODS-A, 10 × 250 mm, 5 μm, 3 mL/min)) (YMC Co., Ltd., Kyoto, Japan). Medium-pressure preparation liquid chromatography (MPLC) was performed on a Bona-Agela CHEETAHTM HP100 (Beijing Agela Technologies Co., Ltd., Beijing, China) \[[@B10-marinedrugs-16-00335]\].

3.2. Fungal Material {#sec3dot2-marinedrugs-16-00335}
--------------------

As described previously in Reference \[[@B6-marinedrugs-16-00335]\].

3.3. Fermentation and Extraction {#sec3dot3-marinedrugs-16-00335}
--------------------------------

As described previously in Reference \[[@B6-marinedrugs-16-00335]\].

3.4. Isolation {#sec3dot4-marinedrugs-16-00335}
--------------

The organic extract was subjected to vacuum liquid chromatography over a silica gel column, using a gradient elution with petroleum ether-CH~2~Cl~2~-MeOH to give six fractions (fractions 1--6). Guided by LC-MS-UV data, fraction 3 (6.5 g) eluted with CH~2~Cl~2~-MeOH (97:3) was applied on a C-18 ODS column using a stepped gradient elution of MeOH-H~2~O, yielding five subfractions (fractions 3.1--3.5). Fraction 3.4, which eluted with MeOH-H~2~O (75:25) was chromatographed on SephadexLH-20 with CH~2~Cl~2~-MeOH (1:1), and further separated by MPLC (C-18 ODS) using MeOH-H~2~O (a gradient elution, 30--100%), to furnish five subfractions (fractions 3.4.1--3.4.5). Fractions 3.4.1 was purified by semi-preparative HPLC (MeOH-H~2~O (55:45)), to afford compound **1** (4.0 mg, *t*~R~ 18.5 min). Fraction 3.4.5 was also purified by semi-preparative HPLC, first using a gradient elution by MeOH-H~2~O (30--100%), and then MeCN-H~2~O (50--90%) to afford compounds **2** (3.0 mg, *t*~R~ 22.5 min) and **3** (4.0 mg, *t*~R~ 25.0 min).

**5-*epi*-asperdichrome (1):** pale yellow powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ −6.6 (*c* 0.1, CHCl~3~); ECD (MeOH) λ (nm) (Δε): 326 (+12.5), 273 (+0.4), 249 (+2.5), 220 (−53.5); UV (MeOH) *λ*~max~ (log *ε*): 242 (2.10), 318 (3.46) nm; ^1^H-NMR and ^13^C-NMR (see [Table 1](#marinedrugs-16-00335-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00335-t002){ref-type="table"}); HR-ESI-MS \[M + H\]^+^ *m*/*z* 639.1721 (calcd. for C~32~H~31~O~14~, 639.1708, error = 1.9432 ppm), \[M + Na\] *m*/*z* 661.1538 (calcd. for C~32~H~30~O~14~Na, 661.1528, error = 1.6056 ppm).

**Versicolone N (2):** pale yellow powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ −43.0 (*c* 0.1, CHCl~3~); ECD (MeOH) λ (nm) (Δε): 360 (−16.5), 318 (+49.7), 237 (−91.5), 218 (−3.5); UV (MeOH) *λ*~max~ (log *ε*): 238 (2.30), 313 (3.16) nm; ^1^H-NMR and ^13^C-NMR (see [Table 1](#marinedrugs-16-00335-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00335-t002){ref-type="table"}); HR-ESI-MS \[M + H\]^+^ *m*/*z* 639.1702 (calcd. for C~32~H~31~O~14~, 639.1708, error = −1.0639 ppm), \[M + NH~4~\] *m*/*z* 656.1976 (calcd. for C~32~H~34~O~14~N, 656.1974, error = 0.2826 ppm).

**Versicolone O (3):** pale yellow powder; $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{20}$ −114.8 (*c* 0.1, CHCl~3~); ECD (MeOH) λ (nm) (Δε): 349 (−41.5), 315 (+48.0), 235 (−80.7), 220 (−13.0); UV (MeOH) *λ*~max~ (log *ε*): 240 (2.25), 315 (3.26) nm; ^1^H-NMR and ^13^C-NMR (see [Table 1](#marinedrugs-16-00335-t001){ref-type="table"} and [Table 2](#marinedrugs-16-00335-t002){ref-type="table"}); HR-ESI-MS \[M + H\]^+^ *m*/*z* 639.1703 (calcd. for C~32~H~31~O~14~, 639.1708, error = −0.7571 ppm), \[M + Na\] *m*/*z* 661.1522 (calcd. for C~32~H~30~O~14~Na, 661.1528, error = −0.8306 ppm).

3.5. Assay of Cytotoxicity {#sec3dot5-marinedrugs-16-00335}
--------------------------

These biological evaluations were carried out as previously reported in Reference \[[@B11-marinedrugs-16-00335]\].

3.6. Assay of Antimicrobial Activity {#sec3dot6-marinedrugs-16-00335}
------------------------------------

The microorganism suspension (198 μL, 10^6^ cfu/mL) in autoclaved growth medium (peptone (20 g/L), beef extract (3 g/L), NaCl (5 g/L) for bacteria; peptone (20 g/L), yeast extract (10 g/L), glucose (20 g/L) for *Candida albicans*)) was added to each well of 96-well plates. Solutions (40 mM) of the compounds and positive drugs were made up in DMSO and dispensed into 96-well plates using the 2× microdilution method, to give 16 concentrations in the range of 200--0.006 μM. Incubated at 28 °C for 24 h, and the lowest concentration that gave complete growth inhibition was recorded as the minimum inhibitory concentration (MIC).

4. Conclusions {#sec4-marinedrugs-16-00335}
==============

In summary, UPLC-MS guided chemical investigation led to the discovery of three new tetrahydroxanthone dimers, 5-*epi*-asperdichrome (**1**), versixanthones N (**2**), and O (**3**), from the marine-derived fungus *Aspergillus versicolor* HDN1009. Compound **1** represented the second example of tetrahydroxanthone dimers with a diaryl ether bond linkage. Their absolute configurations, including the axial and central chirality elements were elucidated by NOE experiments and circular dichroism (CD) comparison. Compounds **2** and **3,** exhibited extensive cytotoxicities against five cancer cell lines with IC~50~ values ranging from 1.7 μM to 16.1 μM, whilst compound **1** showed mild activities against four kinds of bacterial strains, with MIC values ranging from 100 μM to 200 μM.

The following are available online at <http://www.mdpi.com/1660-3397/16/9/335/s1>, Figures S1--S7: 1D, 2D NMR and HRESIMS spectra of 5-*epi*-asperdichrome (**1**), Figures S8--S14: 1D, 2D NMR and HRESIMS spectra of versixanthone N (**2**), Figures S15--S21: 1D, 2D NMR and HRESIMS spectra of versixanthone O (**3**).

###### 

Click here for additional data file.
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marinedrugs-16-00335-t001_Table 1

###### 

^1^H NMR data of compounds **1**--**3** (500 MHz, CDCl~3~, TMS, *δ* ppm, *J* in Hz).

  -----------------------------------------------------------------------------------------------------
  No.     1                       Asperdichrome            2                      3
  ------- ----------------------- ------------------------ ---------------------- ---------------------
  2       6.36 d (8.4)            6.39, d (8.2)            \--                    6.62 d (8.4)

  3       7.30 t (8.3)            7.28, t (8.2)            7.69 d (8.4)           7.18 d (8.4)

  4       6.80 d (8.4)            6.76, d (8.2)            6.69 d (8.4)           \--

  5       3.95 d (11.3)           4.12 d (1.4)             3.94 d (11.1)          3.82 d (11.1)

  6       2.42 m                  2.14, m                  2.46 m                 2.34 m

  7       2.72 dd (6.4, 10.6)\    2.52, dd (18.8, 11.6)\   2.74 dd (6.3, 19.3)\   2.69 m
          2.29 dd (11.0, 15.4)    2.40, dd (18.8, 6.3)     2.32 dd (10.7, 19.2)   

  11      1.17 d (5.9)            1.18, d (6.3)            1.18 d (6.4)           1.08 d (6.3)

  13      3.72 s                  3.69 s                   3.70 s                 3.66

  1-OH    \--                                              11.49 s                11.41 s

  8-OH    15.78 s                 16.0, s                  13.75 brs              13.68 brs

  2′      \--                     \--                      6.51 s                 \--

  3′      7.22 d (8.9)            7.22, d (8.7)            \--                    \--

  4′      6.57 d (8.9)            6.57, d (8.7)            \--                    6.56 s

  5′      3.94 d (11.3)           3.94, d (11.1)           4.14 dd (5.0, 12.6)    4.33 dd (5.0, 12.4)

  6′      2.43 m                  2.40, m                  2.12 m; 2.00, m        2.23 m; 2.10, m

  7′      2.76 dd (6.1, 10.4);\   2.75, dd (18.7, 5.8)\    2.62 m                 2.66 m
          2.32 dd (4.1, 8.2)      2.32, dd (18.7, 10.9)                           

  11′     1.18 d (5.7)            1.17, d (6.8)            2.12 s                 2.23 s

  13′     3.70 s                  3.72, s                  3.74 s                 3.73 s

  1′-OH   11.35 s                 11.4, s                  11.25 brs              11.44 brs

  8′-OH   13.75 s                 13.7, s                  13.77 brs              13.86 brs
  -----------------------------------------------------------------------------------------------------

marinedrugs-16-00335-t002_Table 2

###### 

^13^C NMR data of compounds **1**--**3** in CDCl~3~ (125 MHz, CDCl~3~, TMS, *δ* ppm).

  ------------------------------------------
  No.    1       Asperdi-\   2       3
                 chrome              
  ------ ------- ----------- ------- -------
  1      158.7   160.0       159.3   161.9

  2      109.5   110.9       117.1   110.5

  3      135.6   136.6       141.0   140.2

  4      111.9   113.0       107.8   114.7

  4a     160.2   160.8       158.5   155.9

  5      77.9    72.4        76.9    76.6

  6      29.2    30.1        29.3    29.2

  7      37.8    35.1        36.2    36.1

  8      182.5   186.4       177.7   177.3

  8a     102.7   103.2       101.6   101.4

  9      180.2   181.7       187.1   187.2

  9a     110.8   112.0       106.9   107.0

  10a    84.9    86.2        85.0    84.7

  11     18.0    17.9        18.0    17.9

  12     170.1   173.5       170.5   169.9

  13     53.0    53.7        53.2    53.0

  1′     158.7   154.1       159.3   161.9

  2′     136.8   137.8       111.8   118.4

  3′     130.3   131.5       150.2   149.8

  4′     107.6   109.1       115.7   109.1

  4a′    155.5   157.9       155.7   157.8

  5′     77.9    77.6        71.5    71.9

  6′     29.3    31.1        23.5    23.9

  7′     36.3    37.1        27.5    27.6

  8′     178.3   179.6       177.3   177.8

  8a′    101.6   103.3       101.1   101.3

  9′     186.9   188.7       186.8   186.7

  9a′    107.9   109.1       105.1   104.5

  10a′   84.9    86.8        84.7    84.5

  11′    18.0    18.3        21.1    21.5

  12′    170.2   172.1       169.8   170.4

  13′    53.2    53.4        53.1    53.2
  ------------------------------------------

marinedrugs-16-00335-t003_Table 3

###### 

Inhibitory effects of **1**--**3** on six tumor cells.

  Comp.     IC~50~ (μM)                               
  --------- ------------- ------ ------ ------ ------ ------
  1         \>30          \>30   \>30   \>30   \>30   \>30
  2         1.7           2.7    8.5    8.8    9.1    \>30
  3         1.8           8.1    6.7    8.5    16.1   \>30
  Dox ^a^   0.2           0.02   0.5    0.8    0.3    0.2

^a^ Dox stands for doxorubicin hydrochloride, which was used as a reference drug.

marinedrugs-16-00335-t004_Table 4

###### 

Inhibitory effects of **1** on six kinds of microorganisms.

  Comp.           MIC (μM)                                                   
  --------------- ----------- ----------- ----------- ----------- ---------- ----------
  1               100         200         200         \>200       100        \>200
  Positive Drug   0.781 ^a^   0.391 ^a^   0.781 ^a^   0.391 ^a^   1.56 ^a^   3.13 ^b^

^a^ Ciprofloxacin used as a reference drug for bacteria; ^b^ Nystatin used as a reference drug for *Candida albicans*.
